ME Stock: 14 Things for Investors to Know About 23andMe Following Its Nasdaq Debut

investorplace2021-06-18

23andMe(NASDAQ:ME) stock is on the move Friday after the company made its public debut on the Nasdaq Exchange yesterday.

Here’s everything investorsneed to know about the company and it going public.

  • To start off with, 23andMe didn’t use an initial public offering (IPO) for its debut.
  • Instead, the company combined with special purpose acquisition company (SPAC)VG Acquisition.
  • That SPAC merger closed on Wednesday, which saw shares of ME stock start trading publically on Thursday.
  • The merger resulted in it raising $592 million in gross proceeds, which it plans to use in expanding its consumer health and therapeutics businesses.
  • 23andMe is keeping its current leadership team, but with some minor changes.
  • That includes two executives from VG Acquisition joining the company’s Board of Directors.
  • 23andMe is a consumer genetics and research company.
  • It was founded in 2006 and is headquartered in Sunnyvale, Calif.
  • The goal of the company is to better help its customers understand their own genetic information.
  • Its work has also resulted in several authorizations for genetic health risk reports from the U.S. Food and Drug Administration (FDA).
  • The company uses its research into the human genome to develop drugs to treat a variety of diseases.
  • That includes oncology, respiratory, and cardiovascular diseases.
  • Trading for ME stock is starting off heavy today with some 1.1 million shares trading hands.
  • That’s approaching its average daily trading volume of 1.2 million shares.

ME stock was down 3.8% in early trading on Friday after surging higher during trading on Thursday.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
82